Catenae Innovation PLC (LON:CTEA) has said it will provide the data management platform for a pilot coronavirus (COVID-19) programme being rolled out by an unnamed Fortune 500 American professional services and construction company.
The tests will be supplied and administered its partner BHA-Medical Limited with Catenae securely processing the results via its GDPR-compliant technology before sending them to the individual employees.
The data will also be fed into Public Health England’s database for use by the NHS Test and Trace service.
The pilot, which started on January 28, 2021, will run for the next 12 weeks. And, while it is not expected to generate substantial revenues, it “endorses Catenae’s COVID-19 testing proposition”, investors were told.
In a statement, Catenae chief executive Guy Meyer said: “It is a significant milestone for Catenae to be providing its data management platform as part of a COVID-19 testing trial to a global corporation of this calibre.
“Businesses fully appreciate that even though vaccines are a significant part of managing this pandemic, regular testing of their workforces helps mitigate the risks of infectious outbreaks that interrupt their operations and weaken business resilience.
“Our platform helps them maintain operational effectiveness as best they can in the current circumstances through having up-to-date test result information about the COVID-19 health status of their working populations wherever they are.”